AU2022425198A1 - Aminotetraline activators of serotonin receptors - Google Patents

Aminotetraline activators of serotonin receptors Download PDF

Info

Publication number
AU2022425198A1
AU2022425198A1 AU2022425198A AU2022425198A AU2022425198A1 AU 2022425198 A1 AU2022425198 A1 AU 2022425198A1 AU 2022425198 A AU2022425198 A AU 2022425198A AU 2022425198 A AU2022425198 A AU 2022425198A AU 2022425198 A1 AU2022425198 A1 AU 2022425198A1
Authority
AU
Australia
Prior art keywords
compound
formula
compounds
alkyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022425198A
Other languages
English (en)
Inventor
Tanweer Khan
Robert B. Perni
Glenn Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Therapeutics Inc
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of AU2022425198A1 publication Critical patent/AU2022425198A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022425198A 2021-12-27 2022-12-27 Aminotetraline activators of serotonin receptors Pending AU2022425198A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163294030P 2021-12-27 2021-12-27
US63/294,030 2021-12-27
PCT/US2022/082403 WO2023129909A1 (en) 2021-12-27 2022-12-27 Aminotetraline activators of serotonin receptors

Publications (1)

Publication Number Publication Date
AU2022425198A1 true AU2022425198A1 (en) 2024-07-18

Family

ID=86898315

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022425198A Pending AU2022425198A1 (en) 2021-12-27 2022-12-27 Aminotetraline activators of serotonin receptors

Country Status (6)

Country Link
US (3) US11827580B2 (enExample)
EP (1) EP4457203A4 (enExample)
JP (1) JP2024547131A (enExample)
AU (1) AU2022425198A1 (enExample)
CA (1) CA3242479A1 (enExample)
WO (1) WO2023129909A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
EP4457203A4 (en) * 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
WO2024124056A1 (en) * 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045180B2 (ja) * 1977-05-17 1985-10-08 第一製薬株式会社 ２−アミノテトラリン誘導体
FR2691145A1 (fr) 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5807897A (en) * 1996-03-01 1998-09-15 Zeneca Limited Aminotetralin derivative and compositions and method of use thereof
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
US6201025B1 (en) 1998-10-07 2001-03-13 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
WO2001009120A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
DK1859798T3 (en) 2001-03-29 2016-03-21 Lilly Co Eli N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
BRPI0713736A2 (pt) * 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
US20080318957A1 (en) 2007-05-11 2008-12-25 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
WO2011047165A1 (en) 2009-10-16 2011-04-21 Southern Illinois University Edwardsville Methods for treating memory impairment
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
GB201409516D0 (en) 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US10454900B2 (en) 2015-09-25 2019-10-22 Mcafee, Llc Remote authentication and passwordless password reset
CN110177581B (zh) 2016-11-16 2023-01-03 通用医疗公司 髓过氧化物酶显像剂
WO2019084338A1 (en) 2017-10-25 2019-05-02 University Of South Florida DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
EP4417596B1 (en) 2017-11-06 2026-04-29 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a-beta-42 oligomer formation
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
AU2019324952B2 (en) 2018-08-22 2024-10-24 University Of Technology Sydney NBOMe test
JP7731868B2 (ja) 2019-08-02 2025-09-01 エースロット，インコーポレイテッド ＴＤＰ－４３、α－シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
AU2020386445B2 (en) 2019-11-19 2025-12-18 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US12534425B2 (en) 2020-06-29 2026-01-27 Gilgamesh Pharmaceuticals, Inc. Phenalkylamines and methods of treating mood disorders
CN119285527A (zh) 2020-06-30 2025-01-10 瑞安神经科学公司 色胺前药
JP2024512796A (ja) 2021-04-01 2024-03-19 テラン バイオサイエンシーズ インク． サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物
EP4337220A4 (en) 2021-05-11 2025-07-02 Saint Josephs Univ SELECTIVE, PARTIAL, AND POLARIZED 5-HT2A AGONISTS WITH UTILITY IN VARIOUS DISORDERS
WO2022261263A1 (en) 2021-06-08 2022-12-15 Gilgamesh Pharmaceuticals, Inc. Methods of treating neuropsychiatric disorders
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
CA3239571A1 (en) 2021-12-15 2023-06-22 Noel Aaron Powell Fused pyrrolidine psychoplastogens and uses thereof
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
WO2024124056A1 (en) 2022-12-07 2024-06-13 Entheogenix Biosciences, Inc. Novel sulfoximine activators of serotonin receptors
EP4637736A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Prodrugs of dimethoxyphenylalkylamine activators of serotonin receptors
EP4637735A1 (en) 2022-12-22 2025-10-29 ATAI Therapeutics, Inc. Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
EP4680236A2 (en) 2023-03-16 2026-01-21 ATAI Therapeutics, Inc. 3-alkylamine indole activators of serotonin receptors
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Also Published As

Publication number Publication date
CA3242479A1 (en) 2023-07-06
US20230202965A1 (en) 2023-06-29
US20250282708A1 (en) 2025-09-11
EP4457203A4 (en) 2025-12-17
US12344570B2 (en) 2025-07-01
US11827580B2 (en) 2023-11-28
EP4457203A1 (en) 2024-11-06
JP2024547131A (ja) 2024-12-26
US20240300885A1 (en) 2024-09-12
WO2023129909A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
EP4457203A1 (en) Aminotetraline activators of serotonin receptors
US12351537B2 (en) Dimethoxyphenylalkylamine activators of serotonin receptors
US20230117791A1 (en) SUBSTITUTED 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES FOR TREATING BRAIN DISORDERS
US7098233B2 (en) 5-halo-tryptamine derivatives used as ligands on the 5-HT6 and/or 5-HT7 serotonin receptors
TW201716406A (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
US20260078090A1 (en) N-substituted indoles as 5-hydroxytryptamine (5-ht) serotonin receptor agonists and antagonists
MXPA01005905A (es) Ligandos selectivos de receptores de 5-ht6.
US20230159544A1 (en) Azepino-indoles for the treatment of neurological and psychiatric disorders
WO2024192150A2 (en) 3-alkylamine indole activators of serotonin receptors
EP4637735A1 (en) Dimethoxyphenyl heteroaromatic alkylamine activators of serotonin receptors
KR20230066311A (ko) 삼환형 사이코플라스토겐 및 이의 용도
WO2023051759A1 (zh) 三环化合物及其制备方法
CN121969619A (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
US5446049A (en) Azanoradamantanes for treatment of conditions responsive to 5-HT agonists and/or antagonists
JP2025541942A (ja) ヨヒンビン誘導体、その調製方法、医薬組成物及び使用
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
Zhu et al. Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2
CN117500487A (zh) 血清素受体的二甲氧基苯基烷基胺激活剂
JP2006502974A (ja) 置換環縮合イミダゾール誘導体：ｇａｂａａ受容体リガンド
Herold et al. Synthesis of new hexahydro-and octahydropyrido [1, 2-c] pyrimidine derivatives with an arylpiperazine moiety as ligands for 5-HT1A and 5-HT2A receptors. Part 4
JP2025532560A (ja) 神経変性障害及び癌の治療における化合物及びその使用